Liste modèle des médicaments essentiels

Anti-D immunoglobulin

Section	Indications
Human immunoglobulins ◦ Parenteral > General injections > IV: 250 µg in single-dose vial ◦ Parenteral > General injections > IM: 250 µg in single-dose vial	Maternal care for red cell antibodies Rh incompatibility reaction

Anti-rabies immunoglobulin

Section	Indications
Human immunoglobulins ◦ Parenteral > General injections > IM: 150 IU per mL in vial ◦ Parenteral > Locoregional injections > Other: 150 IU per mL in vial	Rabies

Anti-tetanus immunoglobulin

Section	Indications
Human immunoglobulins ◦ Parenteral > General injections > IM: 500 IU in vial	Tetanus

C1 esterase inhibitor

Section	Indications
Human immunoglobulins ◦ Parenteral > General injections > IV: 500 IU in vial powder for injection	Hereditary angioedema

Coagulation factor IX complex

Section	Indications
Coagulation factors	Therapeutic equivalent to coagulation factor IX, plasma-derived pour Coagulation defects, purpura or other haemorrhagic or related conditions Therapeutic equivalent to coagulation factor IX, plasma-derived pour Haemophilia B

Coagulation factor IX, plasma-derived

Section	Indications
Coagulation factors ◦ Parenteral > General injections > IV: 500 IU in vial powder for injection; 1000 IU in vial powder for injection	Coagulation defects, purpura or other haemorrhagic or related conditions Haemophilia B

Coagulation factor IX, recombinant

Section	Indications
Coagulation factors ◦ Parenteral > General injections > IV: 250 IU per mL in vial lyophilized powder for solution for injection; 500 IU in vial lyophilized powder for solution for injection; 1000 IU in vial lyophilized powder for solution for injection; 1500 IU in vial lyophilized powder for solution for injection; 2000 IU in vial lyophilized powder for solution for injection; 3000 IU in vial lyophilized powder for solution for injection; 4000 IU in vial lyophilized powder for solution for injection	Haemophilia B

Coagulation factor VIII, plasma-derived

Section	Indications
Coagulation factors ◦ Parenteral > General injections > IV: 250 IU in vial powder for injection; 500 IU in vial powder for injection; 1000 IU in vial powder for injection	Haemophilia A

Coagulation factor VIII, recombinant

Section	Indications
Coagulation factors ◦ Parenteral > General injections > IV: 250 IU in vial lyophilized powder for solution for injection; 500 IU in vial lyophilized powder for solution for injection; 1000 IU in vial lyophilized powder for solution for injection; 1500 IU in vial lyophilized powder for solution for injection; 2000 IU in vial lyophilized powder for solution for injection; 3000 IU in vial lyophilized powder for solution for injection; 4000 IU in vial lyophilized powder for solution for injection	Haemophilia A

Cryoprecipitate (native)

Section	Indications
Blood and blood components	Therapeutic equivalent to cryoprecipitate (pathogen-reduced) pour Coagulation defects, purpura or other haemorrhagic or related conditions Therapeutic equivalent to cryoprecipitate (pathogen-reduced) pour Obstetric haemorrhage Therapeutic equivalent to cryoprecipitate (pathogen-reduced) pour Haemophilia A Therapeutic equivalent to cryoprecipitate (pathogen-reduced) pour Von Willebrand disease

Cryoprecipitate (pathogen-reduced)

Section	Indications
Blood and blood components ◦ Injection: frozen liquid in bag or lyophilized powder in vial containing: ◦ > 50 IU Factor VIII ◦ > 100 IU vWF ◦ > 140 mg clottable fibrinogen per unit	Coagulation defects, purpura or other haemorrhagic or related conditions Obstetric haemorrhage Haemophilia A Von Willebrand disease

Dextran 40

Section	Indications
Plasma substitutes ◦ .	Hypovolaemia

Dextran 70

Section	Indications
Plasma substitutes ◦ Parenteral > General injections > IV: 6% injectable solution	Hypovolaemia

Fresh-frozen plasma

Section	Indications
Blood and blood components ◦ Parenteral > General injections > IV:	Blood transfusion without reported diagnosis

Normal immunoglobulin

Section	Indications
Human immunoglobulins ◦ Parenteral > General injections > IV: 5% protein solution; 10% protein solution ◦ Parenteral > General injections > IM: 16% protein solution ◦ Parenteral > General injections > SC: 15% protein solution; 16% protein solution	Primary immunodeficiencies Mucocutaneous lymph node syndrome Langerhans cell histiocytosis

Platelets

Section	Indications
Blood and blood components ◦ Parenteral > General injections > IV:	Blood transfusion without reported diagnosis

Polygeline

Section	Indications
Plasma substitutes ◦ Parenteral > General injections > IV: 3.5% injectable solution ◦ Parenteral > General injections > IV: 3.5% in solution	Therapeutic equivalent to dextran 70 pour Hypovolaemia Hypovolaemia

Red blood cells

Section	Indications
Blood and blood components ◦ Parenteral > General injections > IV:	Blood transfusion without reported diagnosis

Whole blood

Section	Indications
Blood and blood components ◦ Parenteral > General injections > IV:	Blood transfusion without reported diagnosis